Lixte Biotechnology Holdings, Inc. Share Price
LIXTLixte Biotechnology Holdings, Inc. Stock Performance
Open $3.19 | Prev. Close $3.12 | Circuit Range N/A |
Day Range $3.12 - $3.19 | Year Range $0.64 - $6.14 | Volume 300 |
Average Traded $3.16 |
Lixte Biotechnology Holdings, Inc. Share Price Chart
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Lixte Biotechnology Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
25-Feb-26 | $3.19 | $3.12 | +0.00% |
25-Feb-26 | $3.19 | $3.12 | +3.65% |
24-Feb-26 | $3.02 | $3.01 | +2.56% |
23-Feb-26 | $2.86 | $2.94 | -5.78% |
20-Feb-26 | $3.12 | $3.12 | +2.13% |
18-Feb-26 | $3.05 | $3.05 | -7.01% |
17-Feb-26 | $3.28 | $3.28 | +6.84% |